Transitioning CLL FISH analysis into the molecular biomarker era

Dr. Tracy Tucker, PhD, FCCMG

Clinical Cytogeneticist and Molecular Geneticist, Cancer Genetics and Genomics Laboratory, BC Cancer, British Columbia, Canada & Clinical Associate Professor, University of British Columbia, British Columbia, Canada

Dr Tucker runs the molecular genetics rotation for UBC pathology residents and has an interest in education as well as trouble-shooting molecular assays for clinical application.

In this presentation, Dr. Tucker shares her experience of how OGT’s NGS panel, SureSeq™ CLL + CNV, has streamlined her laboratory workflow and enabled the detection of various aberrations in key genes implicated in chronic lymphocytic leukaemia (CLL) progression, including single-nucleotide variants (SNVs), indels, and copy number variants (CNVs). This alleviates the burden of running multiple assays and delivers comprehensive results with a single NGS analysis.

Recent publications from the speaker

1. Do unbalanced MYC break-apart FISH patterns indicate the presence of a MYC rearrangement?
2. ALK+ hyaline‐vascular Castleman disease: A new kid on the block
3. Primary pure carcinoid tumor of the testis: Radiology, pathology and molecular correlation

Disclaimer

This presentation is intended for educational purposes only and does not replace independent professional judgment. Statements of fact and opinions expressed are those of the presenters individually and, unless expressly stated to the contrary, are not the opinion or position of the Oxford Gene Technology Group (OGT). OGT does not endorse or approve, and assumes no responsibility for, the content, accuracy or completeness of the information presented.

SureSeq™: For Research Use Only; Not for Use in Diagnostic Procedures.